Rapid biosensor development using plant hormone receptors as reprogrammable scaffolds

Jesús Beltrán1,2,12, Paul J. Steiner3,12, Matthew Bedewitz3,12, Shuang Wei4,12, Francis C. Peterson5, Zongbo Li6, Brigid E. Hughes5, Zachary Hartley1,2, Nicholas R. Robertson7, Angélica V. Medina-Cucurella8, Zachary T. Baumer2,3, Allison C. Leonard3,12, Sang-Youl Park3,1, Brian F. Volkman6,9, Dmitri A. Nusinow9, Wenwan Zhong6, Ian Wheeldon2,10, Sean R. Cutler1,2,11 and Timothy A. Whitehead4

A general method to generate biosensors for user-defined molecules could provide detection tools for a wide range of biological applications. Here, we describe an approach for the rapid engineering of biosensors using PYR1 (Pyrabactin Resistance 1), a plant abscisic acid (ABA) receptor with a malleable ligand-binding pocket and a requirement for ligand-induced heterodimerization, which facilitates the construction of sense–response functions. We applied this platform to evolve 21 sensors with nanomolar to micromolar sensitivities for a range of small molecules, including structurally diverse natural and synthetic cannabinoids and several organophosphates. X-ray crystallography analysis revealed the mechanistic basis for new ligand recognition by an evolved cannabinoid receptor. We demonstrate that PYR1-derived receptors are readily ported to various ligand-responsive outputs, including enzyme-linked immunosorbent assay (ELISA)-like assays, luminescence by protein-fragment complementation and transcriptional circuits, all with picomolar to nanomolar sensitivity. PYR1 provides a scaffold for rapidly evolving new biosensors for diverse sense–response applications.

Designing sensitive, specific and portable biosensors remains a difficult problem in biotechnology. A number of protein scaffolds have been co-opted from nature or designed from scratch to develop sensors for user-defined molecules, including bacterial allosteric transcription factors1–2, G-protein-coupled receptors3 and computationally redesigned binding proteins4–6, among others7–9. Each of these technologies has been successful in creating biosensors for a given application; however, they are limited by types of output signals available (e.g., transcriptional regulation) and rely on a limited palette of ligands. Methods to generate biosensors for user-defined molecules would accelerate many areas of biotechnology.

Chemically induced dimerization (CID) provides an appealing mechanism for coupling sensing to actuation; two proteins form a stable heterodimer only in the presence of a small molecule. Because they rely on a single protein–protein interaction, CID sensors can be used to build modular protein architectures that regulate transcription, control protein localization and degradation and modulate cell signaling10. However, in the CID systems typically exploited for sensing, ligand binding is shared between the binding partners, which necessitates redesign of the entire interface.

The ABA sensing system11,12 functions through a naturally occurring CID mechanism13 where ligand recognition by PYR1 leads to the formation of a stable PYR1–ligand–protein phosphatase (PP2C) complex that inhibits phosphatase activity. This system is unique, because ligand recognition occurs exclusively within PYR1, which simplifies the engineering of new CID modules. In addition, the phosphatase acts analogously to a coreceptor, because its binding to PYR1 lowers ligand off rates and boosts apparent affinity up to ~100-fold13,14. Thus, micromolar PYR1 binders in isolation can function as nanomolar sensors in combination with the phosphatase. Here, we exploit these beneficial traits using the Arabidopsis PYR1-PP2C system, PYR1-HAB1, to design sensors for diverse chemical classes. Our data show that high-density mutagenesis of this scaffold enables rapid development of sense–response actuators portable to in vitro and in vivo control systems.

Results and discussion
We have previously shown that PYR1 can be repurposed to create an agrochemical receptor that functions in planta to modulate stress tolerance15; in that work, receptors were isolated from a library of variants created by single-site saturation mutagenesis. We reasoned that a structure-guided approach would facilitate the design of a larger collection of stable double mutants and ultimately enable the recognition of more ligands. There are 25 residues in PYR1’s ligand-binding pocket that make close contact to ABA and, therefore, 475 possible single mutants that can be combined to create 108,300 double mutants. We used our knowledge of the conserved receptor activation mechanism to remove six positions. To avoid combining unstable single mutants in the new library, we also used

1Department of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, USA. 2Institute for Integrative Genome Biology, University of California, Riverside, Riverside, CA, USA. 3Department of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, USA. 4Department of Biochemistry, University of California, Riverside, Riverside, CA, USA. 5Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA. 6Department of Chemistry, University of California, Riverside, Riverside, CA, USA. 7Department of Bioengineering, University of California, Riverside, Riverside, CA, USA. 8Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI, USA. 9Donald Danforth Plant Science Center, St. Louis, MO, USA. 10Department of Chemical and Environmental Engineering, University of California, Riverside, Riverside, CA, USA. 11Center for Plant Cell Biology, University of California, Riverside, Riverside, CA, USA. 12These authors contributed equally: Jesús Beltrán, Paul J. Steiner, Matthew Bedewitz, Shuang Wei. 13e-mail: wheeldon@ucr.edu; cutler@ucr.edu; timothy.whitehead@colorado.edu
β(Y2H) staining data show different receptor responses to JWH-015 by to yield PYR1JWH-015, which harbors four mutations. The yeast two-hybrid five hits that were subsequently optimized by two rounds of DNA shuffling for mutants that respond to the synthetic cannabinoid JWH-015 yielding c, Representative screen results. The DSM library was screened for sensors using Y2H growth selections in the presence of a ligand of using double-mutant oligo pools. The combined pools were screened by NM12,15 in two subpools, one using single-mutant oligos and another (3QN1).

Fig. 1 | Protein structure-guided design of high-affinity PYR1-based cannabinoid sensors. a, The 19 side chains of residues in PYR1’s binding pocket targeted for double-site mutagenesis (DSM) are shown along with ABA (yellow) and HAB1’s W385 ‘lock’ residue and water network (3QN1). b, Sensor evolution pipeline. The PYR1 library was constructed by NM to in two subpools, one using single-mutant oligos and another using double-mutant oligo pools. The combined pools were screened for sensors using Y2H growth selections in the presence of a ligand of interest. c, Representative screen results. The DSM library was screened for mutants that respond to the synthetic cannabinoid JWH-015 yielding five hits that were subsequently optimized by two rounds of DNA shuffling to yield PYR1\textsuperscript{Ynm-015}, which harbors four mutations. The yeast two-hybrid (Y2H) staining data show different receptor responses to JWH-015 by β-galactosidase activity.

the Rosetta protein design software to predict the stability of the 361 single mutants at the remaining 19 positions. This analysis identified four positions that are particularly sensitive to mutation and were therefore restricted to a small number of amino acids in the final library; the remaining sites were allowed to mutate to any amino acid except cysteine or proline (Supporting File 1). Together, these steps condensed the library to a collection of 37,797 single and double nonsynonymous mutants (42,743 total mutants), which we constructed using site-directed mutagenesis. A total of 36,452 mutants were constructed using a pool of 301 single-mutant oligos in two sequential rounds of single-site nicking mutagenesis (NM)\textsuperscript{15}; 6,291 of the mutants involved residues too close to one another (within eight residues) to be combined using single-mutant oligonucleotides and were instead constructed by NM using a pool of double-mutant oligonucleotides (Fig. 1b)\textsuperscript{11}. The two libraries were combined to yield the double-site mutagenesis (DSM) pocket library for subsequent screening. The DSM library was deep sequenced and determined to possess >99.8% of the desired double mutants (Supporting File 1).

With the improved library in hand, we set out to test its efficiency in a number of screens for biosensors. We first focused on developing cannabinoid sensors, in part to develop diagnostic reagents for synthetic cannabinoid mimics sold in products like ‘Spice’, which have caused many hospitalizations\textsuperscript{19} and deaths\textsuperscript{20,21}. We screened for PYR1 mutants responsive to any one of a panel of 28 cannabinoids, screening for mutants responsive to 30 μM of each test chemical (Extended Data Fig. 1 shows chemical structures). Selections were accomplished in a Y2H strain in which expression of URA3 rescues uracil auxotrophy via PYR1 binding to HAB1. Before selection, mutations that produced ligand-independent URA3 activation were removed by a negative selection in the presence of 5-fluoroorotic acid. Our initial positive selections identified double mutants responsive to JWH-015 (Fig. 1c) and five other naphthoylindoles, as well as cannabicyclohexanol (CP 47,497), a different chemical scaffold and one of the active ingredients in ‘Spice’; this demonstrates that our library can yield sensors in a single screening step. Additional sensors were acquired by iteratively screening diversified cannabinoid-biased sublibraries that were created by shuffling hit receptors against both the parental DSM and previous single-site mutant (SSM) libraries. Ultimately, these efforts identified 12 PYR1-derived cannabinoid receptors that recognize 14 compounds, including sensors for CBDA, Δ⁹-THC and 4F-MDMB-BUTINACA (4F-MDMB), from a total of 28 cannabinoids screened (Fig. 2a,b and Extended Data Fig. 1). Overall, mutations in nine out of the 19 residue positions targeted in the parental library were obtained in the cannabinoid receptors (K59, V81, V83, L87, A89, Y120, F159, A160 and V164), along with two additional sites (H115 and M158) present in the DSM library used for DNA shuffling and affinity maturation. We note that in two cases, our selections converged on the identical sequences; receptors responsive to JWH-072 and JWH-015, closely related naphthoylindoles that differ by only a single methyl substituent, yielded nearly identical evolved sequences. Similarly, the sensors obtained for the closely related compounds 4F-MDMB and AB-PINACA contained identical mutations (Supporting File 2). In addition, wild-type PYR1 did not respond to any of the target ligands screened, nor did our evolved high-affinity sensors respond to ABA (Supplementary Fig. 1); collectively, these data show that PYR1’s ligand-binding pocket can be reprogrammed to recognize target molecules.

Most synthetic cannabinoids share a central indole or indazole scaffold. We anticipated that our evolved cannabinoid receptors might show cross-reactivity. To explore this, we tested several high-affinity sensors for cross-reactivity to cognate ligands (Supplementary Figs. 1 and 2). Although these tests indicate some cross-reactivity, particularly for PYR1\textsuperscript{9} and to a lesser degree PYR1\textsuperscript{10}, in all cases, on-target sensitivity was at least tenfold higher than the off-target sensitivity. Thus, PYR1-derived sensors can provide sensitive and selective ligand detection, although this will vary by receptor and chemical.

To understand the underlying molecular basis for cannabinoid recognition by our evolved receptors, we sought to obtain the structure of a receptor–cannabinoid–HAB1 complex and targeted two high-affinity sensors, PYR1\textsuperscript{9} and PYR1\textsuperscript{10}. In our experience,
PYL2 (a close relative of PYR1) forms crystals more readily than PYR1. PYL2 shares 88% pairwise sequence identity with PYR1 for the 25 ABA-proximal positions, and structures of the two proteins are globally alignable to 0.55 Å root mean squared deviation. We, therefore, transposed mutations conferring ligand-selective responsiveness to PYL2, creating PYL2\textsuperscript{4F} and PYL2\textsuperscript{WIN}, which both retain nanomolar ligand responsiveness (Supplementary Fig. 2). In addition, we created a stabilized, catalytically inactive derivative of HAB1 less prone to oxidative inactivation by employing computational redesign, yielding ΔN-HAB1\textsuperscript{T} (derived from a HAB1 truncation that contains its PYR1-binding catalytic domain). This variant harbors 15 mutations, displays a ~7 °C increase in apparent T\textsubscript{m}, and retains high-affinity ligand-dependent binding to PYR1, as measured by a yeast surface display assay that uses PYR1\textsuperscript{Δ4} (H60P, N90S), a monomeric double mutant optimized for yeast surface display\textsuperscript{(a)} (Supplementary Fig. 3 and Supporting File 1). Using these engineered proteins in matrix screens, we obtained diffraction quality crystals for a ternary PYL2\textsuperscript{WIN}/WIN 55,212-2/ΔN-HAB1\textsuperscript{T} complex, whose structure was solved by molecular replacement (1.9 Å resolution; Supplementary Table 1). Diffraction quality PYL2\textsuperscript{4F} crystals were not obtained. Several rounds of structural refinement were carried out before modeling WIN 55,212-2 into the ligand-binding pocket’s unbiased electron density (Supplementary Fig. 4). A real-space correlation coefficient of 0.967 calculated between the unbiased electron density and (+)-WIN 55,212-2 indicates agreement between the model and observed electron density. We note that the evolved receptor recognizes the biologically active (+)-WIN 55,212-2 stereoisomer, although selections were conducted using a racemate (Supplementary Fig. 2).

A central feature of ABA recognition by native sensors is the formation of a closed-receptor conformer that is stabilized by a hydrogen-bond network between a structurally conserved water, ABA’s ring ketone, main-chain amides in the gate and latch loops, and HAB1’s W385 Trp-`lock’ residue\textsuperscript{[a–c]}. In our PYL2\textsuperscript{WIN} structure, WIN 55,212-2’s naphthoylindole ketone functions analogously to ABA’s ketone and is coordinated through water-mediated hydrogen...
Fig. 3 | PYR1-based sensors are portable to diverse CID-based output systems demonstrated with PYR1\textsuperscript{WIN}. a, Phosphatase inhibition. Ligand-dependent inhibition of ΔN-HAB1 phosphatase activity by recombinant receptors using a fluorogenic substrate. Inhibition expressed relative to mock controls (n = 3). b, Gene activation. Ligand-induced gene activation in S. cerevisiae using an engineered Z4-PYR1/VP64-ΔN-HAB1 genetic circuit. Whole-cell fluorescence generated from an integrated Z4_c::CYC1core-GFP-CYC1t reporter is shown (12 h after ligand addition; n = 3). c, Split luciferase complementation. Addition of ligand results in luminescence from NLucN-PYR1/NLucC-ΔN-HAB1 (n = 3). d, PYR1 ELISA-like immunonasas. Immobilized receptors recruit biotinylated ΔN-HAB1\textsuperscript{+} in response to ligand, and colorimetric signal is generated by a secondary streptavidin-HRP conjugate. Assays conducted in fivefold dilutions of saliva, urine, serum and blank saline are shown, with the lower limit of detection (LOD; Methods) of each assay shown (n = 3). Data points represent the mean, and the 95% confidence interval is shown on fits in a–d as gray shading and stated in square brackets along with the EC\textsubscript{50} values. e, Receptor cross-reactivity evaluation in PYR1 ELISAs. The cannabinoids shown were assayed for signal generation at 2 μM. + CNTRL, PYR1\textsuperscript{WIN} tested with 2 μM ABA (n = 3); RLU, relative luminescence unit. Protein parts: DBD, DNA binding domain; AD, activation domain; MBP, maltose binding protein; SA, streptavidin. Chemicals: THC, tetrahydrocannabinol; WIN, (+)-WIN 55,212-2.

bonds to backbone P92 in the gate, R120 in the latch and HAB1’s W385 lock residue (Fig. 2c).

Analysis of the PLY2-WIN structure also revealed that ligand binding is stabilized by an extensive network of hydrophobic contacts and a water-mediated contact to WIN’s morpholine oxygen (Supplementary Fig. 4). In comparison to PYR1, PYR1\textsuperscript{WIN} harbors three mutations (K59Q, F159A and A160I), and our structure illuminates their roles in allowing favorable binding. The most conspicuous effect is a relief of steric clash that would occur between F159 and WIN’s naphthalene ring in a wild-type receptor (Supplementary Fig. 4). In comparison to PYR1, PYR1\textsuperscript{WIN} harbors a water-mediated hydrogen-bond network at the base of the pocket (Fig. 2d and Supplementary Fig. 4). Thus, WIN’s binding to PYL2\textsuperscript{WIN} involves a combination of polar and hydrophobic contacts, which contrasts with its binding mode in the human cannabinoid receptor CB2, where binding involves exclusively hydrophobic contacts and a more extended ligand conformer\textsuperscript{23} (Fig. 2e). In addition, the structure illustrates the success of our HAB1 redesign, showing that ΔN-HAB1\textsuperscript{+}’s main chain is nearly superimposable with that of wild-type (0.85 Å root mean squared deviation) and that the key rotamers for residues involved in receptor interactions are maintained (Supplementary Fig. 3). Collectively, these data provide a mechanistic basis for the sensitive and selective cannabinoid recognition by our evolved receptor, illuminate the mutability of PYR1’s ligand-binding pocket and validate our computational HAB1 redesign.

In principle, the PYR1-HAB1 CID mechanism enables rapid construction of multiple sense-response outputs, as has been demonstrated with other designed CID sensors\textsuperscript{1}. To explore the portability of the designed PYR1-HAB1 system, we selected two high-affinity receptors for evaluation of in vitro HAB1 inhibition, yeast transcriptional activation circuits and in vivo protein-fragment complementation with split luciferase. PYR1\textsuperscript{WIN} and PYR1\textsuperscript{Δ4} displayed nanomolar half-maximum effective concentration (EC\textsubscript{50}) values using an inhibition assay that detects receptor activation by changes in HAB1 phosphatase activity using a fluorogenic substrate (EC\textsubscript{50} PYR1\textsuperscript{WIN}; 72 nM; PYR1\textsuperscript{Δ4}; 102 nM; Fig. 3 and Supplementary Fig. 5). Fusion of the transcriptional activator VP64 to ΔN-HAB1 and a zinc-finger DNA-binding domain to PYR1\textsuperscript{WIN} enabled inducible GFP expression from a synthetic cassette integrated into the genome of Saccharomyces cerevisiae with an EC\textsubscript{50} of 28 nM. The same transcriptional circuit built with PYR1\textsuperscript{Δ4} responded to 4F-MDMB with an EC\textsubscript{50} of 23 nM. Similar success was achieved with the NanoLuc split luciferase systems\textsuperscript{14};
the luminescence and fluorescence reporting modes may be advantageous for ligand detection using low-cost instrumentation and/or in remote settings using engineered living cells.

N-HAB1 CID mechanism enables portability to both in vitro and ΔN-HAB1 responded with an EC50 of 56 nM, and NLucΔ-N-HAB1 responded with an EC50 of 25 nm. Taken together, these results show that the PYR1/ΔN-HAB1 CID mechanism enables portability to both in vitro and in vivo formats and can be deployed in multiple outputs. Moreover, the luminescence and fluorescence reporting modes may be advantageous for ligand detection using low-cost instrumentation and/or in remote settings using engineered living cells.

Synthetic cannabinoids are frequently modified to evade detection by routine drug testing. For example, 4F-MDMB is a relatively new indazole that first appeared in 2018 and rapidly became one of the most prevalent synthetic cannabinoids used in the United States25–27. Although mass spectrometry methods can sensitively detect this and most synthetic cannabinoids, lower-cost and selective acetylcholinesterase inhibitors that were among the first organophosphates, an important class of toxic, non-PETs, we tested it with spiked urine, blood and saliva samples and observed reliable detection of picomolar concentrations (LOD: 515 pM in urine, 1,105 pM in blood serum and 305 pM in saliva; Fig. 3d), which compares favorably with existing immunoassay kits that typically report low-nanomolar LODs35. In addition, minimal cross-reactivity between the PYR1WIN-M and PYR1WIN-M and a panel of 14 cannabinoids was observed using this detection format (Fig. 3e and Supplementary Fig. 5). Combined with our other results, these data further demonstrate that PYR1's native CID mechanism can be harnessed to develop multiple sense-response outputs and demonstrate that our optimized ELISA-like test enables selective and sensitive detection of target ligands using evolved PYR1-based sensors.

Given the success of the PYR1 scaffold as a platform for cannabinoid sensing, we sought to explore the possibility of rapidly generating sensors for a second class of compounds. To do so, we developed a hybrid sandwich-assay in which the PYR1 sensor is surface immobilized and then coimmobilized with biotinylated AN-HAB1 and the ligand of interest. Detection of ternary complexes can then be quantified using streptavidin-linked horse-radish peroxidase (HRP), as is commonly done with ELISAs. We developed an ABA-detection system using PYR1M (LOD 2 nM, 0.7 ng ml−1) and then adopted this optimized format for PYR1Δ-M and PYR1WIN-M (Supplementary Fig. 5 and Supporting File 1). To evaluate the assay's performance in forensically relevant samples, we tested it with spiked urine, blood and saliva samples and observed reliable detection of picomolar concentrations (LOD: 515 pM in urine, 1,105 pM in blood serum and 305 pM in saliva; Fig. 3d), which compares favorably with existing immunoassay kits that typically report low-nanomolar LODs35. In addition, minimal cross-reactivity between the PYR1WIN-M and PYR1WIN-M and a panel of 14 cannabinoids was observed using this detection format (Fig. 3e and Supplementary Fig. 5). Combined with our other results, these data further demonstrate that PYR1's native CID mechanism can be harnessed to develop multiple sense-response outputs and demonstrate that our optimized ELISA-like test enables selective and sensitive detection of target ligands using evolved PYR1-based sensors.

Given the success of the PYR1 scaffold as a platform for cannabinoid sensing, we sought to explore the possibility of rapidly generating sensors for a second class of compounds. To do so, we screened single and multisite mutational libraries against various different organophosphates, an important class of toxic, non-selective acetylcholinesterase inhibitors that were among the first insecticides broadly used in the 20th century. Due to their effects

Fig. 4 | Facile development of potent, selective and portable organophosphate sensors. a. Summary of biosensor screening results for a panel of ten organophosphates. The compounds screened are clustered by similarity (blue indicates more similar) using a distance matrix of pairwise Tanimoto similarity scores, calculated in ChemMine 19. The molecules that yielded hits are shown in bold type; the minimal ligand concentrations required for Y2H signal generation for optimized receptors (Methods) are indicated (Supplementary Fig. 12 shows additional details). b. The optimized PYR1ΔAD and PYR1ΔAD are high-affinity sensors. Optimized receptors were tested for responses to nanomolar concentrations of diazinon and pirimiphos-methyl, respectively, as evidenced by Y2H assays and receptor-mediated inhibition of HAB1 phosphatase activity in vitro. PYR1ΔAD (EC50 = 36 nM [32,40]); PYR1ΔAD (EC50 = 58 nM [50,67]). Wild-type PYR1 was used as a control (gray lines). c, PYR1-derived receptors are portable. PYR1ΔAD and PYR1ΔAD were tested in a protein-fragment complementation system based on split luciferase reconstitution with NLucΔ-PYR1/NLucΔ-HAB1 fusions in yeast (PYR1ΔAD, EC50 = 24 nM [12,50]; PYR1ΔAD, EC50 = 19 nM [undf, 29]). d, e, PYR1ΔAD and PYR1ΔAD are selective for their evolved target ligands. d, Y2H (top) and in vitro phosphate inhibition assays (bottom) were used to profile receptor responses; the receptors no longer bind the native ligand ABA. Pirimiphos-methyl and diazinon were tested 20 nM, ABA, tested at 5,000 nM in Y2H assays. e, Characterization of receptor selectivity using a Z4-PYR1/VP64-ΔN-HAB1 gene activation circuit in the presence of the activating ligands shown (Supporting File 1 shows quantitative analyses of EC50 values). In all cases, the symbol represents the mean, and the error bars show 1 s.d. and may be smaller than the symbol. All data points represent the mean of triplicate data (n = 3), and error bars represent the standard deviation.
on nontarget organisms, most organophosphates have been banned in the United States, and they present an ongoing environmental monitoring challenge. We screened PYR1 libraries against a panel of 10 organophosphates (diazinon, pirimiphos, dimethoate, chlorfenvipron, parathion, disulfoton, azinphos, bromophos, malathion and monocrotophos), none of which activated wild-type PYR1 (Supplementary Fig. 1; see Supporting File 1 for library details). These screens yielded receptors for diazinon, pirimiphos, dimethoate and chlorfenvipron at concentrations between 5 and 100 μM (Supporting File 3). In addition, we screened the new DSM library against the same set of 10 compounds and obtained receptors for seven of these (Supplementary Fig. 6). To improve receptor affinity, we used recombination-based mutagenesis for four organophosphate receptors (diazinon, pirimiphos, chlorfenvipron and dimethoate) by shuffling hits against parent libraries. This approach was repeated four times, reducing the ligand concentration at each step to ultimately yield improved sensors for these two compounds (Fig. 4a,b). The diazinon-responsive variant PYR1DIAZI is a heptapeptide mutant (E8G, V81Y, L87M, F108Y, N119S, S122Q, E130G, F159G and A160V), and the pirimiphos-responsive variant PYR1PYM is an octapeptide mutant (K59R, S92M, N119S, S122Q, E130G, F159T, A160T and V174A). These optimized sensors were also immediately portable to the split luciferase system with low-nanomolar sensitivity (Fig. 4c). Together, these data demonstrate that the PYR1 ligand-binding pocket can mutate to accommodate organophosphate ligands and provide a general system for developing organophosphate sensors.

To address the selectivity profiles of the evolved organophosphate receptors, we characterized their cross-reactivity to target ligands, given the close structural similarity of diazinon and pirimiphos. Both HAB1 inhibition and 2H assay showed that the evolved receptors are highly selective towards their on-target ligands (Fig. 4d). PYR1PYM was activated by low-nanomolar concentrations of pirimiphos but required high-nanomolar to low-micromolar diazinon concentrations for activation above background levels. Similar results were observed with the PYR1DIAZI receptor, and neither receptor was activated by ABA. In a strict test of specificity, we used our yeast transcription circuit to characterize the off-target responses of these engineered receptors to a panel of six chemically similar organophosphates. The PYR1DIAZI EC50 to diazinon was greater than tenfold lower than all other molecules profiled (Fig. 4e). For example, PYR1DIAZI responded with an EC50 of 1.1 μM to azinphos but with an EC50 of 43 nM to diazinon. Other off-target ligands responded with higher EC50 values and with lower activation levels (Supporting File 1). Similarly, the PYR1DIAZI receptor showed good discrimination between its on-target ligand diazinon and other organophosphates when tested at 20 μM in the ELISA-format mode (Supplementary Fig. 7). Lastly, we examined how receptor selectivity changed over the evolutionary trajectory of the PYR1DIAZI sensor. Off-target ligand responses remained weak throughout the evolutionary process and decreased as affinity increased (Supplementary Fig. 7). Collectively, these data show that improvements in affinity were not obtained at the cost of increased promiscuity and that high-affinity and high-selectivity can be evolved using the PYR1 scaffold.

Using our designed PYR1-HAB1 system, we isolated sensors for 21 of the 38 compounds screened, which included a diverse set of ligands that fall into distinct chemotypes (Extended Data Fig. 2). Although structurally diverse, many of the ligands screened contain a carbonyl functional group that, as observed with WIN 55,212-2, can engage the Trp-lock to stabilize activated receptors (Fig. 2 and Extended Data Fig. 3). Prior work has shown that other H-bond acceptors (e.g., nitriles and others) can function in place of a carbonyl to activate both wild-type and engineered PYR1 receptors12-13 (Extended Data Fig. 3). In addition, our evolved PYR1CP sensor recognizes a ligand lacking a C=O (Fig. 2). Thus, the chemical scope of ligands compatible with our system should be quite broad. However, even if there is a bias towards carbonyl-containing ligands, approximately one-third of natural products and drugs contain a carbonyl12 and provide a large set of ligands. When coupled to the high hits obtained with our DSM library, it should be possible to evolve molecular switches controlled by a large number of drugs, natural products or metabolites. Although many technologies for chemically regulated dimerization have been developed, our system is unique, because it empowers the design systems controlled by user-specified ligands, which is particularly useful when specific properties (such as low cost or low toxicity) are required in downstream applications. Thus, the PYR1/HAB1 system provides an easily reprogrammable chemical-induced dimerization module that will enable new applications in biotechnology, synthetic biology and medicine.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41587-022-01364-5.

Received: 17 May 2021; Accepted: 17 May 2022; Published online: 20 June 2022

References
1. Glasgow, A. A. et al. Computational design of a modular protein sense-response system. Science 366, 1024–1028 (2019).
2. Taylor, N. D. et al. Engineering an allosteric transcription factor to respond to new ligands. Nat. Methods 13, 177–183 (2016).
3. Urban, D. J., Gerona, R. R. & Schwartz, M. D. Synthetic cannabinoid-related illnesses and deaths. N. Engl. J. Med. 373, 103–107 (2015).
4. Shui, S. et al. A rational blueprint for the design of chemically-controlled protein switches. Nat. Commun. 12, 5754 (2021).
5. d’Oelnsnit, S., Nguyen, V., Alper, H. S. & Ellington, A. D. Evolving a generalist biosensor for bicuspid monoterpenes. ACS Synth. Biol. 11, 263–272 (2022).
6. Rottinghaus, A. G., Xi, C., Amrofell, M. B., Yi, H. & Moon, T. S. Engineering ligand-specific biosensors for aromatic amino acids and neurotransmitters. Cell Syst. https://doi.org/10.1016/j.cels.2021.10.006 (2021).
7. Stanton, B. Z., Chory, E. J. & Crabtree, G. R. Chemically induced proximity in biology and medicine. Science 359, eaaso5902 (2018).
8. Park, S.-Y. et al. Aquochemical control of plant water use using engineered abscisic acid receptors. Nature 520, 545–548 (2015).
9. Medina-Cucurella, A. V. et al. User-defined single pot mutagenesis using unamplified oligo pools. Protein Eng. Des. Sel. 32, 41–45 (2019).
10. Ma, Y. et al. Regulators of P2CP phosphate activity function as abscisic acid sensors. Science 324, 1064–1068 (2009).
11. Srodkiewicz, I. et al. Closely related receptor complexes differ in their ABA selectivity and sensitivity. Plant J. 61, 25–35 (2010).
12. Wrenbeck, E. E. et al. Plasmid-based one-pot saturation mutagenesis. Nat. Methods 13, 928–930 (2016).
13. Tait, R. J., Caddick, D., Mountain, D., Hill, S. L. & Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin. Toxicol. 54, 1–13 (2016).
14. Trecki, J., Gerona, R. R. & Schwartz, M. D. Synthetic cannabinoid-related illnesses and deaths. N. Engl. J. Med. 373, 103–107 (2015).
15. Stein, P. J. et al. 2019 A yeast surface display platform for plant hormone receptors: toward directed evolution of new biosensors. Annu. Rev. Pharmacol. Toxicol. 59, 25–47 (2019).
16. White, C. M. The pharmacologic and clinical effects of illicit synthetic cannabinoids. J. Clin. Pharmacol. 57, 297–304 (2017).
17. Miyazono, K.-I. et al. Structural basis of abscisic acid signalling. Nature 462, 602–608 (2009).
18. Miyazono, K.-I. et al. Structural basis of abscisic acid signalling. Nature 462, 609–614 (2009).
19. Yin, P. et al. Structural insights into the mechanism of abscisic acid signalling by PYL proteins. Nat. Struct. Mol. Biol. 16, 1230 (2009).
23. Xing, C. et al. Cryo-EM structure of the human cannabinoid receptor CB2-Gi signaling complex. *Cell.* **180**, 645–654.e13 (2020).
24. Dixon, A. S. et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. *ACS Chem. Biol.* **11**, 400–408 (2016).
25. Hasegawa, K. et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. *Forensic Toxicol.* **33**, 380–387 (2015).
26. New Psychoactive Substances Discovery Dashboard. *Synthetic Cannabinoids Trend Report* https://www.npsdiscovery.org/wp-content/uploads/2021/04/2021-Q1_Synthetic-Cannabinoids_Trend-Report.pdf.
27. National Forensic Laboratory Information System. *NFLIS-Drug December 2020 Snapshot* https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS_Snapshot_122020.pdf.
28. Spinelli, E. et al. Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. *Drug Test. Anal.* **7**, 467–474 (2015).
29. Vaidya, A. S. et al. Dynamic control of plant water use using designed ABA receptor agonists. *Science* **366**, eaaw8848 (2019).
30. Vaidya, A. S. et al. 2017 A rationally designed agonist defines subfamily iia abscisic acid receptors as critical targets for manipulating transpiration. *ACS Chem. Biol.* **12** 2842–2848.
31. Peterson, F. C. et al. Structural basis for selective activation of ABA receptors. *Nat. Struct. Mol. Biol.* **17**, 1109–1113 (2010).
32. Zuccotto, F. Pharmacophore features distributions in different classes of compounds. *J. Chem. Inf. Comput. Sci.* **43**, 1542–1552 (2003).
33. Backman, T. W. H., Cao, Y. & Girke, T. ChemMine tools: an online service for analyzing and clustering small molecules. *Nucleic Acids Res.* **39**, W486–W491 (2011).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Methods

PYR1 library design. The design of the PYR1 pocket double-mutant library was performed with a combination of mutant stability analysis with the Rosetta molecular modeling suite and manual curation (Supplementary Information). The final library design incorporated the 19 mutations. Fifteen positions (50, 83, 89, 92, 94, 108, 117, 120, 122, 141, 159, 160, 163, 164 and 167) were allowed to mutate to all amino acids except cysteine or proline. Four positions (62, 81, 87 and 110) were restricted to smaller amino acid subsets.

Construction of the PYR1 DSM library. The PYR1 DSM sub-libraries were constructed by NM as previously described35,36. Briefly, a library encoding pairs of mutations separated by at least eight amino acids was constructed by two sequential rounds of single-site NM using pooled primers (IDT). In parallel, an oligo pool (Agilent) containing primers encoding all pairs of proximate mutations (those separated by fewer than eight amino acids) was used in a single round of NM. The two libraries were then transformed into a hybrid vector by ligation and pooled to give the complete DSM library. See Supplementary Information for complete details of library construction, as well as libraries used for isolation of organophosphate sensors.

V2H screening of mutagenized PYR1 libraries. Selection experiments for mutant receptors that respond to new ligands were conducted as previously described35,36. Briefly, the PYR1 DSM mutant library was transformed into INV99 harboring pACT-HAB1. Negative selections were conducted to remove receptors that bind HAB1 in a ligand-independent fashion (i.e., constitutive receptors) by growing the library on solids containing 0.1% 3-trifluoroacetic acid. A positive library was collected and used in subsequent selections for cells responsive to 30 μM cannabinoid ligands (purchased from Cayman Chemical as Drug Enforcement Administration–exempt preparations; Supplementary Fig. 2) on SD-Trp,-Leu,-Ura media. Colonies supporting uracil-independent growth at 30 °C were isolated after 3 days, retested to confirm ligand-dependent growth on SD-Trp,-Leu,-Ura plates with and without test chemical and then validated by β-galactosidase staining.

Receptor ligand affinity optimization and new cannabinoid binders were obtained by generating and screening secondary shuffle (CB-S) libraries. To construct CB-S libraries, gene sequences of PYR1 cannabinoid-responsive variants were combined with the original PYR1 DSM library and the PYR1 DSM library in a ratio of 40:40:40, respectively, followed by recombinant-based mutagenesis, using a molecular modeling suite and manual curation (NeXT; see ref. 13). The resulting shuffled fragments were cloned into the V2H pBD vector by restriction/ligation procedures. Ligation products were transformed into Escherichia coli, colonies were collected and plasmid DNA was extracted. In total, three independent shuffle libraries (CB-S1, CB-S2 and CB-S3) were generated at different stages of the optimization and rescoring process. CB-S1 and CB-S3 were screened with 10 to 0.1 μM ligand, depending on the sensitivity of the parental mutants. CB-S2 was screened with 0.05 to 0.025 μM ligand. The organophosphates screened (Supplementary Fig. 3 shows structures) were obtained from Sigma-Aldrich; screens of multisite mutagenized PYR1 libraries and affinity optimization details are provided in the Supplementary Methods.

Ligand/receptor-mediated PP2C inhibition assays. Coding sequences of the cannabinoid sensors were cloned into the protein expression vector pET28a to encode 6His-tag–receptor fusions. Constructs were sequenced and transformed into the BL21 (DE3) pLYS S. coli strain for heterologous expression with IPTG (1 mM), followed by recombinant-based mutagenesis, using affinity chromatography, as previously reported35. In vitro validation of evolved sensors was performed by using recombinant sensors and ΔN-HAB1 (HAB1 Δ1–178, ref. 13) proteins, as previously described35. Ligand/receptor-dependent inhibition of PP2C activity was performed essentially as previously reported using 25 nM ΔN-HAB1 with either 25 nM titrated PYR1 or 50 nM titrated PYR1(106). Cannabinoid concentration curves ranged from 4 to 10,000 nM, and median inhibitory concentrations for PP2C inhibition were obtained via fluorescence measurement in the presence of 1 mM 4-methylumbelliferyl phosphate (pNPP)37.

Cross-reaction tests for high-affinity cannabinoid and organophosphate sensors. High-affinity sensors were tested for cross-reaction using both Y2H and in vitro PP2C assays. PYR1(i106) and PYR1(i106) sensors specificity was examined by X-gal staining using increasing amounts of WIN 55,212-2, 4F-MDMB-BUTINACA, AB-PINACA and JWH-072 (0, 50, 100, 200, 500 and 1,000 nM) and by in vitro PP2C inhibition assays (4–10,000 nM) with EC50 estimation for each receptor/ligand combination using nonlinear fitting with the [apontosis] versus response function in GraphPad Prism 9. Similar methods were used to characterize PYR1(i106) and PYR1(i106) sensor selectivity and sensitivity.

Yeast transcriptional activation circuits. PYR1 variants were used to drive gene expression in an inducible genetic circuit by fusing a zinc-finger DNA-binding domain (Z4) to the N terminus of PYR1 and the VP64 activation domain to the C terminus of PYR1. The yeast terminal glucose repression circuit was also fused to the N terminus of ΔN-HAB1. A single 2p plasmid was used to express Z4-PYR1 and SV40-VP64-ΔN-HAB1, whereas the GFP expression cassette (Z4-CYC1 + GFP-CYC1) was integrated at the YPR2A1 site on chromosome XVI. GFP fluorescence induced by each circuit was measured 12 h after ligand addition to 1 μl cultures at 30 °C. Fluorescence was measured by flow cytometry. Briefly, 50 μl resuspended cells was transferred to a 96-well plate for analysis. The fluorescence intensity of each cell was measured using a BD Accuri C6 flow cytometer equipped with auto-ranging. The forward scatter, side scatter and GFP fluorescence (excitation/emission 488/533 nm) were recorded for a minimum of 10,000 events. Descriptions of the cloning procedures and methods used to create organophosphate- and cannabinoid-responsive transcriptional circuits are provided in the Supplementary Methods.

In vivo split luciferase assays. To demonstrate a protein complementation output of PYR1-based cannabinoid sensors, the large and small fragments of split NanoLuc luciferase3 were fused to the N termini of PYR1 variants and ΔN-HAB1 and expressed from a 2 μg plasmid. Ligand was added to yeast cultures 12 h before measuring cell luminescence. A sample of each culture was diluted to an OD600 of 0.2, 0.1 μl of which was transferred to a 96-well plate, the luciferase reagent mixture (Nano-Glo live cell substrate; Promega) diluted to a 1× concentration with DI water was added to the cell sample to a final volume of 200 μl. The relative luminescence signal was measured using a Synergy Neo2 Multi Mode Microplate Reader in luminescence detection mode for 30 min after the addition of the reagents. The relative luminescence signal of each measured sample was taken as the average value of the time course once the signal had reached a plateau. Cloning methods and procedures for all split-luciferase systems are provided in Supplementary Methods.

Construction of PYL2(ΔN) and PYL2(ΔN)-STD. The PYL2 coding sequence cloned in the Y2H pBD vector was used as template to incorporate the corresponding PYR1(i106) and PYR1(i106) homologous residues via site-directed mutagenesis using the QuickChange Lightning Multi Site-Directed mutagenesis kit (Agilent Technologies). Resulting clones PYL2(i106) (K64Q, F165A and V166L) and PYL2(i106) (H119Q, Y124F, G141E, L159A and V166L) were sequenced confirmed and used in the CB-S1 and harboring pACT-HAB1 and tested for ligand activation using uracil-independent growth and X-gal staining experiments. The same method was used to generate a PYL2(i106) version in a protein expression vector for crystallization studies.

Expression, purification and characterization of variant HAB1s and PYLs. Except where noted, all proteins were expressed as N-terminal 6His-MBP fusions primarily using the medium and method as described in ref. 13. For crystallographic structures, PYL2 and ΔN-HAB1 were expressed in E. coli and purified as described previously38. Assays for phosphate activity and apparent Ki, measured via thermal challenge using yeast surface display, were performed essentially as previously described11.

HAB1 stabilization. ΔN-HAB1 and other stabilized dead ΔN-HAB1 variants were designed as follows: loss of activity was encoded by either R199A, D243A or R199A and D204A; C186S, C274S mutations are known to improved redox stability39. Mutations conferring improved stability were identified by the Rosetta-based web server PROSS (all options default) using three separate HAB1 structures as starting points (Protein Data Bank (PDB) accession numbers 4WV0, 4DS8 and 3KB340). Consensus mutations shared among all structures were identified, yielding 22 potential mutations at 16 positions. These mutations were screened using empirical filters on distance from HAB1 interface and contact number43. Manual curation was used to identify the final design set of 11 mutations at 11 positions.

ELISA-like assays. PYR1 was immobilized overnight in clear plates and blocked with KPL milk diluent in buffer CBSB (CBSM). Detection was performed via binding a streptavidin-HRP conjugate to biotinylated ΔN-HAB1 followed by incubation with a commercial TMB reagent. For detection in biospecimens, well blocking was done with 1% BSA in buffer CBS (CBSB). The spiked biospecimens (that is human serum, saliva, or urine) were diluted 5-fold and mixed with the biotinylated ΔN-HAB1 in CBSB, before being added to the PYR1-modified wells. LOD was determined by the response data in the low linear range. The plot of absorbance (A450) versus log (target concentration) was fitted to linear regression and the resultant equation was used to calculate the target concentration that would yield the signal equal to (3× STD+ blank), where STD is the standard deviation of blank.

Crystallization. Purified protein was stored at −80 °C in a buffer containing 20 mM HEPES (pH 7.6), 50 mM sodium chloride, 10 mM diethiothreitol and 10% glycerol. Purified PYL2 and ΔN-HAB1 were mixed in 1:1.05 molar reaction and exchanged into a buffer containing 20 mM HEPES (pH 7.6), 50 mM sodium chloride, 50 mM diethiothreitol and 5 mg/magnesium chloride and 5% glycerol. The contents were then concentrated to 15 mg/ml and incubated with a fivefold molar excess of (±)-WIN 55,212 (Cayman Chemical) for 30 min on ice. Crystallization of the PYL2:WIN-ΔN-HAB1 complex was conducted by sitting drop vapor diffusion at 19°C. Drops were formed by mixing equal volumes of the purified PYL2:WIN-ΔN-HAB1 complex with well solution containing 100 mM Bis-tris propane pH 6.5, 50 mM magnesium chloride and 35% glycerol. The resulting crystals were flash-frozen after passing through a cryoprotection solution consisting of well solution plus 20% glycerol. X-ray diffraction data for
each complex were gathered from a single crystal. Diffraction data was collected at 100 K using the LS-CAT ID-21-F beamline at the Advanced Photon Source (Argonne National Laboratory). Diffraction data were indexed, integrated and scaled using the XDS software package.

Structure determination. The PYL2:WIN-ΔN-HAB1Δ complex structure was solved by molecular replacement using a PYL2-Quinabactin:HAB1 complex (PDB accession number 4LA7) devoid of ligand and water molecules as the search model to evaluate the initial phases. Phenix.AutoMR solved the initial phases and automatically built the majority of residues for both complexes. The resulting models were completed through iterative rounds of manual model building in Coot and refinement with Phenix.refine using translational libration screw-motion (TLS) and individual atomic displacement parameters. A Phenix topology file for the (+)-WIN 55,512 ligand was generated using the PRODRG server (http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg/). The geometry of the final structures was validated using Molprobity. Data collection and refinement statistics for the final PYL2:WIN 55,212-2:ΔN-HAB1Δ complex are listed in Supplementary Table 5, and the coordinates for the structure have been deposited in the PDB with the accession number 7MWN.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
All source data for Figs. 3 and 4 are in the attached ‘Beltran_SourceData_Fig3.xlsx’ and ‘Beltran_SourceData_Fig4.xlsx’ workbooks. Sequences of all sensors described are listed in Supporting File 1. The following plasmids and libraries are available to noncommercial users through Addgene: pJS5646 (Addgene ID 183175); pJS647 (Addgene ID 183176); PYR1 Double Mutant Library - proximal mutations (L007) (Addgene ID 183177); PYR1 Double Mutant Library - distant mutations (L008) (Addgene ID 183178). Raw sequencing reads for the PYR1 double-mutant library have been deposited in the Sequence Read Archive (BioProject accession number PRJNA830502). The coordinates for the structure have been deposited in the PDB with the accession number 7MWN. Source data are provided with this paper.

Code availability
Custom code for evaluating the completeness of the PYR1 double-mutant library has been deposited in Zenodo (https://doi.org/10.5281/zenodo.6493839). Source data are provided with this paper.

References
34. Müller, K. M. et al. Nucleotide exchange and excision technology (NeXT) DNA shuffling: a robust method for DNA fragmentation and directed evolution. Nucleic Acids Res. 33, e117 (2005).
35. Okamoto, M. et al. Activation of dimeric ABA receptors elicits guard cell closure, ABA-regulated gene expression, and drought tolerance. Proc. Natl Acad. Sci. U. S. A. 110, 12132–12137 (2013).
36. Santiago, I. et al. Modulation of drought resistance by the abscisic acid receptor PYL5 through inhibition of clade A PP2Cs. Plant J. 60, 575–588 (2009).
37. D. Elzinga et al. 2019 Defining and exploiting hypersensitivity hotspots to automatically build the majority of residues for both complexes. Nature Research Reporting Summary linked to this article. Further information on research design is available in the Reporting summary. The accession number 7MWN.
Table 5, and the coordinates for the structure have been deposited in the PDB with the accession number 7MWN.

Author contributions
S.R.C., T.A.W. and I.W conceived of the study, and all authors wrote and edited the manuscript. Contributions to the experimental work include library design and construction (T.A.W., A.V.M.-C. and P.J.S.); biosensor isolation, optimization and characterization (J.B., S.-Y.P. and S.R.C.); crystal structure and analysis (F.C.P. and B.E.H.); gene circuit and protein complementation sensors (S.W. and I.W.); PP2C characterization (J.B., S.-Y.P. and S.R.C.); crystal structure and analysis (F.C.P. and B.E.H.); and ELISA-like assays (M.B., T.A.W., Z.T.B., A.C.L. and Z.T.B.); and ELISA-like assays (M.B., T.A.W., Z.T.B., A.C.L. and Z.T.B.).

Competing interests
P.I.S., M.B., T.A.W., S.R.C. and I.W. have filed a provisional patent entitled REAGENTS AND SYSTEMS FOR GENERATING BIOSENSORS (US9738902B2; WO2011139798A2) covering the research in the present work.

Additional information
Extended data are available for this paper at https://doi.org/10.1038/s41587-022-01364-5.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41587-022-01364-5.
Correspondence and requests for materials should be addressed to Ian Wheeler, Sean R. Cutler or Timothy A. Whitehead.
Peer review information Nature Biotechnology thanks Carsten Schultz and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | See next page for caption.
Extended Data Fig. 1 | Chemical diversity of natural and synthetic cannabinoids sensed by engineered PYR1 sensors. (a) Y2H data of sensor hits; each row shows the response of an evolved PYR1 sensor to its target ligand; the sequences of the sensors used are shown in supporting data file 1. (b) Chemical structures of compounds for which at least one PYR1-based biosensor was identified. (c) Chemical structures of compounds for which no PYR1-based biosensor was identified.
Extended Data Fig. 2 | Chemicals subjected to sensor screens using PYR1 DSM library. The 38 chemicals screened in our manuscript were compared pairwise to compute a matrix of Tanimoto distance scores (shown in the heatmap), which was used for hierarchical clustering; blue = small distance (high similarity) and red = higher distance. Sensors were obtained for the 21 compounds in the shaded boxes.
Extended Data Fig. 3 | Diverse H-bond acceptors can stabilize activated PYR/PYL receptors. Diverse H-bond acceptors can stabilize activated PYR/PYL receptors. Structural comparisons of diverse receptor-ligand complexes with the receptor shown in blue and the complexed PP2C (HAB1) is shown in green. (a) In wild-type complexes, the PYR1/ABA/HAB1 complex is stabilized by a hydrogen-bond network coordinated by a central water molecule conserved across ligand-activated receptor X-ray structures (red). The conserved water stabilizes the ternary complex by making contacts to ABA’s cyclohexenone oxygen and PYR1’s P88 main-chain carbonyl oxygen, which serve as H-bond acceptors, and HAB1’s TRP385 indole HN and PYR1’s ARG116 main-chain NH, which serve as H-donors (PDB 3QNI). (b) In the engineered PYL2WIN receptor, WIN 55,212’s naphthoylindole carbonyl oxygen interacts with the conserved water molecule to engage the TRP-lock, mimicking ABA’s carbonyl oxygen. (c) In the engineered PYR1MANDI receptor, mandipropamid’s aryl-alkyl ether oxygens stabilizes the PYR1MANDI/mandipropamid/HAB1 complex via two bound waters that interact with ether oxygens (PDB 4WVO). (d) The rationally designed agonist cyanabactin stabilizes activated PYR1 via an arylnitrile H-bond acceptor that interacts with the conserved water (PDB 5UR6). (e, f) The agonist pyrabactin (with a weak C-Br H-bond acceptor) does not make appreciable contacts with bound water either in homologous PYL1 receptor nor in the engineered PYL2A393F. (e shows PDB ID 3NMT, native PYL1, PDB ID 3NMN is shown in f).
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

☐ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement

☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

☐ The statistical test(s) used AND whether they are one- or two-sided

Only common tests should be described solely by name; describe more complex techniques in the Methods section.

☐ A description of all covariates tested

☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

☐ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

☐ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted

Give P values as exact values whenever suitable.

☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

☐ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection BD Accuri C6+ analysis software or FlowJo software were used to collect flow cytometry data. No custom code was used to collect data.

Data analysis Statistical analysis for all graphical data presented was performed on Graphpad Prism version 9.0. Custom scripts were used for deep sequencing data analysis; these scripts are available on Zenodo under DOI: 10.5281/zenodo.6493839

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. Github). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Accession code for the WIN-PYL2WIN–HAB1T+ structure is listed as 7MWN. Libraries will be made available through AddGene pending University approval.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](http://nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

- **Sample size**: No sample size calculations were performed. The sample size (n) of each experiment is provided in the corresponding figure captions or methods section in the main manuscript and supplementary information files. Sample sizes were chosen to support meaningful conclusions.
- **Data exclusions**: No data were excluded.
- **Replication**: All data are presented in biological duplicate or triplicate as noted in the figure legends.
- **Randomization**: The work does not involve participant groups; therefore, randomization was not relevant to the study.
- **Blinding**: The work does not involve participant groups, therefore, blinding was not relevant to the study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| ☒ Antibodies | ☒ Eukaryotic cell lines |
| ☒ Palaeontology and archaeology | ☒ Animals and other organisms |
| ☒ Human research participants | ☒ Clinical data |
| ✗ Dual use research of concern |

### Methods

- **Involved in the study**
  - ☒ ChiP-seq
  - ✗ Flow cytometry
  - ✗ MRI-based neuroimaging

### Antibodies

- **Antibodies used**: anti-cmyc FITC was used for yeast surface display measurements in Figure S4. Details of this reagent are provided in the materials section of the supporting information.
- **Validation**: anti-cmyc FITC (part no. 130-116-653 used in these studies) was validated as described by the commercial vendor here — [https://www.millennibiotec.com/US-en/products/c-myc-antibody-anti-human-mouse-rat-sh1-26e7-1-3.html#fitc:30-tests-in-60-ul](https://www.millennibiotec.com/US-en/products/c-myc-antibody-anti-human-mouse-rat-sh1-26e7-1-3.html#fitc:30-tests-in-60-ul)

### Flow Cytometry

**Plots**

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

**Methodology**

- **Sample preparation**: The cells were washed with 1 mL PBS buffer twice and resuspended in 1 mL DI water for flow cytometry analysis. For analysis,
| Sample preparation       | 50 μL of resuspended cells were transferred to a 96-well plate with flat bottom, adding DI water up to a final volume of 200 μL. |
|-------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Instrument              | Samples were analyzed using either a BD Accuri C6+ flow cytometry or Sony Biotech SH800.                                                                                               |
| Software                | Samples were analyzed using either BD Accuri C6+ analysis software or FlowJo software.                                                                                                 |
| Cell population abundance | At least 10,000 cells were analyzed in each experiment, gating data is shown in the supporting information.                                                                          |
| Gating strategy         | The standard gating for yeast measurements has been adequately described in previous publications, e.g., Medina-Cucurella A and Whitehead TA (2018) “Characterizing Protein-Protein Interactions Using Deep Sequencing Coupled to Yeast Surface Display”, Methods in Molecular Biology in Protein Complex Assembly, 101-121; the full gating strategy is shown in the SI. |

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.